市場調查報告書

全球前臨床CRO (醫藥品臨床研究委外機構) 市場

Global Preclinical CRO Market Research Report Forecast to 2024

出版商 Market Research Future 商品編碼 909752
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球前臨床CRO (醫藥品臨床研究委外機構) 市場 Global Preclinical CRO Market Research Report Forecast to 2024
出版日期: 2019年07月31日內容資訊: 英文 125 Pages
簡介

本報告提供全球前臨床CRO (醫藥品臨床研究委外機構) 市場的相關調查,市場機會和課題,成長及阻礙因素,投資,價格,各服務、治療領域、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 摘要整理

第2章 市場介紹

  • 定義
  • 調查範圍
  • 市場結構

第3章 調查方法

  • 調查方法
  • 一次調查
  • 二次調查
  • 市場規模的估計
  • 預測模式

第4章 市場動態

  • 概要
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 課題
  • 宏觀經濟指標
  • 趨勢

第5章 市場要素分析

  • 價值鏈分析
  • 波特的五力分析
  • 投資機會
  • 價格分析

第6章 全球市場:各類服務

  • 概要
  • 毒性實驗
  • 生物分析及藥物代謝及藥物動力學(DMPK)研究
  • 其他

第7章 全球市場:各治療領域

  • 概要
  • 腫瘤
  • 中樞神經系統(CNS)障礙
  • 心血管疾病
  • 免疫疾病
  • 呼吸疾病
  • 感染疾病
  • 糖尿病
  • 其他

第8章 全球市場:各終端用戶

  • 概要
  • 製藥及生物醫藥品產業
  • 醫療設備公司
  • 學術機構

第9章 全球市場:各地區

  • 概要
  • 南北美洲
    • 北美
    • 南美
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 中東、非洲地區
    • 中東
    • 非洲

第10章 競爭情形

  • 簡介
  • 企業佔有率分析

第11章 企業簡介

  • IQVIA
  • PAREXEL International Corporation
  • Envigo
  • Charles River
  • Eurofins Scientific
  • ICON PLC
  • PRA Health Sciences (PRA)
  • Medpace
  • Laboratory Corporation of America Holdings
  • Pharmaceutical Product Development, LLC
  • WuXi AppTec
  • MD Biosciences

第12章 附錄

  • 參照資料
  • 相關報告
目錄

Global Preclinical CRO Market: Information by Service (Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies, Others), Application (Oncology, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Immunological Disorders, Respiratory Diseases, Infectious Diseases, Diabetes and Others), by End User (Pharmaceutical and Biopharmaceutical Industries, Medical Device Companies and Academic Institutes) and Region - Forecast till 2024

Market analysis

A preclinical CRO distributes the practice, information and ability that is required to take a therapeutic product or a medical device from its clinical stage to advertising or delivery. Benefitting the growth in subcontracting of non-core purposes, improved abilities of preclinical CROs, the global preclinical CRO market has been principally helped to offer supplementary value-added services, rolling number of drugs in the preclinical phase, economies of production & scale, mutual advantage to the contractor as well as the client and high R&D expenditure. However, its has been noted that the shortage of labor as well as high labor cost, operational variations in the industry is predicted to confine the market growth. The global market for preclinical CRO is expected to drive owing to aspects for example development in outsourcing of non-core functions, boosted abilities of preclinical CROs to offer additional value-added services and heaving number of drugs in preclinical stages. Furthermore, economies of production and scale is a shared advantage to the outworker as well as the client and high R&D outflow are expected to fund the growth of the market in the coming years.

Market segmentation

The collective urge for experimenting new drugs and chemicals as well as dynamic progress in the pharmaceutical and biopharmaceutical segments are expected to drive the market. However, the bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies section is likely to parade the highest CAGR of 8.96% from 2019 to 2024. Innovative technological advances by various companies to deliver healthier services to pharmaceutical companies and is driving the growth of the sector simultaneously. The Key players in the market segmented, can be given by service (i.e. Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies and others), By Application (Immunological Disorders, Respiratory Diseases, Oncology, Diabetes, Cardiovascular Diseases, Infectious Diseases and others), By End User (Medical Device Companies, Academic Institutes, Pharmaceutical and Biopharmaceutical Industries and others), By Region (North America, Europe, Asia-Pacific and Rest of the World).The SWOT Analysis of the Global Preclinical CRO Market can be further customized and can be available as an additional article into the main report. The toxicological testing segment is projected to head the market and roll a substantial CAGR to reach USD 2,476.28 Million by the end of 2024.

Regional analysis

Geographically, the Global Preclinical CRO Market is segmented and targeted into global regions like North America, Asia-Pacific, Middle East and Africa along with the European market. The European market is projected to surpass USD 1,670.19 Million by 2024. The cumulative farm out activities in Europe, low labor cost & engineering cost and accessibility of expert medical force are the reasons driving the growth of the preclinical CRO market in the region. Americas considered to be the largest market share of 40.7% in 2018, and the regional market is projected to list a CAGR of 7.49% throughout the prediction period. Asia-Pacific is expected to register the fastest CAGR. The Indian market is probable to show the uppermost growth rate of 9.44% during the forecast period of 2019 to 2024.

Major players

The bulging players in the Global Preclinical CRO Market. Are compnaies like Pharmaceutical Product Development, LLC (US), MD Biosciences (US)., IQVIA (US), PAREXEL International Corporation (US), Envigo (US), Charles River (US), ICON PLC (Dublin), PRA Health Sciences (US), Medpace (US), Laboratory Corporation of America Holdings (US), WuXi AppTec (China) and Eurofins Scientific (Luxembourg. The players operating in the global preclinical CRO market are focusing on product unveilings, along with intensifying their global footpaths by entering untouched markets.

Table of Contents

1 Executive Summary

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Drivers
    • 4.2.1 Growth in Outsourcing of Non-Core Functions
    • 4.2.2 Enhanced Abilities of Preclinical CROs to Offer Additional Value-Added Services
    • 4.2.3 Surging Number of Drugs in the Preclinical Phase
    • 4.2.4 Economies of Production and Scale
    • 4.2.5 Mutual Benefit to the Contractor as Well as the Client
    • 4.2.6 High R&D Expenditure
  • 4.3 Restraints
    • 4.3.1 Scarcity of Labour and High Labour Cost
    • 4.3.2 Structural Changes in the Industry
  • 4.4 Opportunity
    • 4.4.1 Opportunity for Medical Device Companies to Outsource Preclinical Trials to CROs
  • 4.5 Challenges
    • 4.5.1 Supply Chain Complexity and Third-Party Control
    • 4.5.2 Outdated Clinical Trial Activities
  • 4.6 Macroeconomic Indicators
  • 4.7 Trends

5 Market Factor Analysis

  • 5.1 Value Chain Analysis
    • 5.1.1 R&D
    • 5.1.2 Good Laboratory Practices (GLP)
    • 5.1.3 Pre-Clinical CRO Testing
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Buyers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitutes
    • 5.2.5 Intensity of Rivalry
  • 5.3 Investment Opportunities
  • 5.4 Pricing Analysis

6 Global Preclinical CRO Market, By Service

  • 6.1 Overview
  • 6.2 Toxicology Testing
  • 6.3 Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
  • 6.4 Others

7 Global Preclinical CRO Market, By Therapeutic Area

  • 7.1 Overview
  • 7.2 Oncology
  • 7.3 Central Nervous System (CNS) Disorders
  • 7.4 Cardiovascular Diseases
  • 7.5 Immunological Disorders
  • 7.6 Respiratory Diseases
  • 7.7 Infectious Diseases
  • 7.8 Diabetes
  • 7.9 Others

8 Global Preclinical CRO Market, By End User

  • 8.1 Overview
  • 8.2 Pharmaceutical and Biopharmaceutical Industries
  • 8.3 Medical Device Companies
  • 8.4 Academic Institutes

9 Global Preclinical CRO Market, By Region

  • 9.1 Overview
  • 9.2 Americas
    • 9.2.1 North America
      • 9.2.1.1 US
      • 9.2.1.2 Canada
    • 9.2.2 Latin America
  • 9.3 Europe
    • 9.3.1 Western Europe
      • 9.3.1.1 Germany
      • 9.3.1.2 France
      • 9.3.1.3 UK
      • 9.3.1.4 Italy
      • 9.3.1.5 Spain
      • 9.3.1.6 Rest of Western Europe
    • 9.3.2 Eastern Europe
  • 9.4 Asia-Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia-Pacific
  • 9.5 Middle East & Africa
    • 9.5.1 Middle East
    • 9.5.2 Africa

10 Competitive Landscape

  • 10.1 Introduction
  • 10.2 Company Share Analysis

11 Company Profile

  • 11.1 IQVIA
    • 11.1.1 Company Overview
    • 11.1.2 Financial Overview
    • 11.1.3 Products/Services Offered
    • 11.1.4 Key Developments
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Strategies
  • 11.2 PAREXEL International Corporation
    • 11.2.1 Company Overview
    • 11.2.2 Financial Overview
    • 11.2.3 Products Offering
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Strategies
  • 11.3 Envigo
    • 11.3.1 Company Overview
    • 11.3.2 Financial Overview
    • 11.3.3 Products Offering
    • 11.3.4 Key Developments
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Strategies
  • 11.4 Charles River
    • 11.4.1 Company Overview
    • 11.4.2 Financial Overview
    • 11.4.3 Products/Services Offered
    • 11.4.4 Key Developments
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Strategies
  • 11.5 Eurofins Scientific
    • 11.5.1 Company Overview
    • 11.5.2 Financial Overview
    • 11.5.3 Products/Services Offered
    • 11.5.4 Key Developments
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Strategies
  • 11.6 ICON PLC
    • 11.6.1 Company Overview
    • 11.6.2 Financial Overview
    • 11.6.3 Products/Services Offered
    • 11.6.4 Key Developments
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Strategies
  • 11.7 PRA Health Sciences (PRA)
    • 11.7.1 Company Overview
    • 11.7.2 Financial Overview
    • 11.7.3 Products/Services Offered
    • 11.7.4 Key Developments
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Strategies
  • 11.8 Medpace
    • 11.8.1 Company Overview
    • 11.8.2 Financial Overview
    • 11.8.3 Products/Services Offered
    • 11.8.4 Key Developments
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Strategies
  • 11.9 Laboratory Corporation of America Holdings
    • 11.9.1 Company Overview
    • 11.9.2 Financial Overview
    • 11.9.3 Products/Services Offered
    • 11.9.4 Key Developments
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Strategies
  • 11.1 Pharmaceutical Product Development, LLC
    • 11.10.1 Company Overview
    • 11.10.2 Financial Overview
    • 11.10.3 Products/Services Offered
    • 11.10.4 Key Developments
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Strategies
  • 11.11 WuXi AppTec
    • 11.11.1 Company Overview
    • 11.11.2 Financial Overview
    • 11.11.3 Products/Services Offered
    • 11.11.4 Key Developments
    • 11.11.5 SWOT Analysis
    • 11.11.6 Key Strategies
  • 11.12 MD Biosciences
    • 11.12.1 Company Overview
    • 11.12.2 Financial Overview
    • 11.12.3 Products/Services Offered
    • 11.12.4 Key Developments
    • 11.12.5 SWOT Analysis
    • 11.12.6 Key Strategies

12 Appendix

  • 12.1 References
  • 12.2 Related Reports

List of Tables

  • TABLE 1 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 2 GLOBAL PRECLINICAL CRO MARKET, FOR TOXICOLOGY TESTING, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 3 GLOBAL PRECLINICAL CRO MARKET, FOR BIOANALYSIS AND DRUG METABOLISM AND PHARMACOKINETICS (DMPK) STUDIES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 4 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 5 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 6 GLOBAL PRECLINICAL CRO MARKET, FOR ONCOLOGY, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 7 GLOBAL PRECLINICAL CRO MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 8 GLOBAL PRECLINICAL CRO MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 9 GLOBAL PRECLINICAL CRO MARKET, FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 10 GLOBAL PRECLINICAL CRO MARKET, FOR RESPIRATORY DISEASES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 11 GLOBAL PRECLINICAL CRO MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 12 GLOBAL PRECLINICAL CRO MARKET, FOR DIABETES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 13 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 14 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 15 GLOBAL PRECLINICAL CRO MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRIES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 16 GLOBAL PRECLINICAL CRO MARKET, FOR MEDICAL DEVICE COMPANIES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 17 GLOBAL PRECLINICAL CRO MARKET, FOR ACADEMIC INSTITUTES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 18 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 19 GLOBAL PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
  • TABLE 20 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2018 & 2024 (USD MILLION)
  • TABLE 21 AMERICAS: PRECLINICAL CRO MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 22 AMERICAS: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 23 AMERICAS: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 24 AMERICAS: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 25 NORTH AMERICA: PRECLINICAL CRO MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 26 NORTH AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 27 NORTH AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 28 NORTH AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 29 US: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 30 US: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 31 US: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 32 CANADA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 33 CANADA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 34 CANADA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 35 LATIN AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 36 LATIN AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 37 LATIN AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 38 EUROPE: PRECLINICAL CRO MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 39 EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 40 EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 41 EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 42 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 43 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 44 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 45 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 46 GERMANY: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 47 GERMANY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 48 GERMANY: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 49 FRANCE: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 50 FRANCE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 51 FRANCE: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 52 UK: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 53 UK: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 54 UK: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 55 ITALY: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 56 ITALY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 57 ITALY: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 58 SPAIN: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 59 SPAIN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 60 SPAIN: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 61 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 62 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 63 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 64 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 65 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 66 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 67 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 68 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 69 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 70 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 71 JAPAN: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 72 JAPAN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 73 JAPAN: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 74 CHINA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 75 CHINA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 76 CHINA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 77 INDIA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 78 INDIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 79 INDIA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 80 AUSTRALIA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 81 AUSTRALIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 82 AUSTRALIA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 83 SOUTH KOREA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 84 SOUTH KOREA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 85 SOUTH KOREA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 86 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 87 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 88 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 89 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 90 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 91 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 92 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 93 MIDDLE EAST: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 94 MIDDLE EAST: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 95 MIDDLE EAST: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 96 AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016-2024 (USD MILLION)
  • TABLE 97 AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016-2024 (USD MILLION)
  • TABLE 98 AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2016-2024 (USD MILLION)
  • TABLE 99 KEY DEVELOPMENTS & STRATEGIES

List of Figures

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL PRECLINICAL CRO MARKET: MARKET STRUCTURE
  • FIGURE 3 RESEARCH PROCESS OF MRFR
  • FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 5 MARKET DYNAMICS: GLOBAL PRECLINICAL CRO MARKET
  • FIGURE 6 VALUE CHAIN: GLOBAL PRECLINICAL CRO MARKET
  • FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PRECLINICAL CRO MARKET
  • FIGURE 8 GLOBAL PRECLINICAL CRO MARKET SHARE, BY SERVICE, 2018 (%)
  • FIGURE 9 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2018 & 2024 (USD MILLION)
  • FIGURE 10 GLOBAL PRECLINICAL CRO MARKET SHARE, BY THERAPEUTIC AREA, 2018 (%)
  • FIGURE 11 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2018 & 2024 (USD MILLION)
  • FIGURE 12 GLOBAL PRECLINICAL CRO MARKET SHARE, BY END USER, 2018 (%)
  • FIGURE 13 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2018 & 2024 (USD MILLION)
  • FIGURE 14 AMERICAS: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
  • FIGURE 15 NORTH AMERICA: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
  • FIGURE 16 EUROPE: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
  • FIGURE 17 WESTERN EUROPE: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
  • FIGURE 18 ASIA-PACIFIC: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
  • FIGURE 19 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
  • FIGURE 20 GLOBAL PRECLINICAL CRO MARKET SHARE ANALYSIS 2017 (%)
Back to Top